Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ardelyx

5.47
+0.05000.92%
Post-market: 5.44-0.0300-0.55%19:59 EDT
Volume:2.79M
Turnover:15.17M
Market Cap:1.30B
PE:-32.88
High:5.52
Open:5.46
Low:5.38
Close:5.42
Loading ...

Company Profile

Company Name:
Ardelyx
Exchange:
NASDAQ
Establishment Date:
2007
Employees:
395
Office Location:
400 Fifth Avenue,Suite 210,Waltham,Massachusetts,United States
Zip Code:
02451
Fax:
- -
Introduction:
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Directors

Name
Position
David Mott
Chairman of the board
Michael Raab
Director, President and Chief Executive Officer
Annalisa Jenkins
Director
Gordon Ringold
Director
Richard Rodgers
Director
Robert Bazemore
Director
William Bertrand, Jr.
Director

Shareholders

Name
Position
Michael Raab
Director, President and Chief Executive Officer
Reginal Seeto
Executive Vice President and Chief Operating Officer
Elizabeth Grammer
Senior Vice President and General Counsel
Mark Kaufmann
Chief Financial Officer
David Rosenbaum
Chief Development Officer
Jeremy Caldwell
Executive Vice President and Chief Scientific Officer
Paul Korner
Executive Vice President and Chief Medical Officer